Clinical Trials
215 trialsBreathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
TUPRO
University of Zurich
TraveraRTGx
Travera Inc
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
University of California, San Francisco
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
The Christie NHS Foundation Trust
LEGIT_MC_EVCDA
AI Labs Group S.L
IMMUMELA
Assistance Publique - Hôpitaux de Paris
Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
Institute of Oncology Ljubljana
LegitHealth PH
AI Labs Group S.L
LegitHealthSAN
AI Labs Group S.L
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Amgen
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
University of Wisconsin, Madison
TavieSkin
Pierre Fabre Medicament
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Memorial Sloan Kettering Cancer Center
ICI-PICK
Indiana University
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
MEL-CARE
Ankara Etlik City Hospital
LEAD Melanoma
Novartis
DISSEMELA
Assistance Publique - Hôpitaux de Paris
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
Centre Hospitalier Universitaire de Nīmes
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
AIQ TRAQinform
AIQ Solutions
SBRT
Mayo Clinic
NICO
Bristol-Myers Squibb
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Region Skane
Head and Neck Melanoma; Access to Staging and Surgical Treatment
Hull University Teaching Hospitals NHS Trust
Combi-EU
EuMelaReg gGmbH
OCEANMIST
Pfizer
PREFER
Labcorp Corporation of America Holdings, Inc
TasteSPICIER
University Medical Center Groningen
MOM
Inova Health Care Services
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
St. Luke's Hospital and Health Network, Pennsylvania
AI-DSMM
Linkoeping University
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Pfizer
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Bristol-Myers Squibb
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
ROOT
Taproot Health
DERM-SUCCESS
DermaSensor, Inc.
MS; FTY720
University of British Columbia
Imaging FDG Flare in Melanoma
Abramson Cancer Center at Penn Medicine
SAFEST
Herlev Hospital
Hydrochlorothiazide and Risk of Skin Cancer
Canadian Network for Observational Drug Effect Studies, CNODES
LENVAMEL
Centre Hospitalier Universitaire de Besancon
Utility of Novel BRAF Test for Melanoma
Massachusetts General Hospital
BESPOKE Study of ctDNA Guided Immunotherapy
Natera, Inc.
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
Case Comprehensive Cancer Center
Micro3
Centre Hospitalier Universitaire de Saint Etienne